Press Releases April 23, 2026 04:01 PM

Kiniksa Pharmaceuticals to Report First Quarter 2026 Financial Results on April 28, 2026

Kiniksa Pharmaceuticals to release Q1 2026 financial results and discuss recent portfolio developments on April 28, 2026

By Nina Shah
Share
Twitter Reddit Facebook LinkedIn
KNSA

Kiniksa Pharmaceuticals International announced it will report its first quarter 2026 financial results on April 28, 2026, via a conference call and webcast. The company will also discuss recent portfolio execution. The event will be accessible through the company's website, with a replay available shortly after.

Kiniksa Pharmaceuticals to Report First Quarter 2026 Financial Results on April 28, 2026
KNSA
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Kiniksa Pharmaceuticals will announce Q1 2026 financial results on April 28, 2026.
  • The company will host a live webcast and conference call for investors and media.
  • Kiniksa focuses on developing novel therapies for diseases with unmet needs, particularly cardiovascular indications.

LONDON, April 23, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, April 28, 2026 at 8:30 a.m. Eastern Time to report its first quarter 2026 financial results and recent portfolio execution.

A live webcast will be accessible through the Investors & Media section of the company’s website at www.kiniksa.com. Individuals interested in participating in the call via telephone may register here. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. A replay of the event will also be available on Kiniksa’s website within approximately 48 hours after the event.

About Kiniksa
Kiniksa is a biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating diseases by discovering, acquiring, developing, and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications. Kiniksa’s portfolio of assets is based on strong biologic rationale or validated mechanisms and offers the potential for differentiation. For more information, please visit www.kiniksa.com.

Every Second Counts! ®

Kiniksa Investor & Media Contact
Jonathan Kirshenbaum
(781) 829-3949
[email protected]


Risks

  • Financial results may not meet investor expectations, impacting stock price.
  • Pipeline therapies face typical biopharmaceutical development and commercialization risks.
  • Market competition and regulatory approvals could affect future growth and portfolio valuation.

More from Press Releases

Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease Jun 13, 2026 Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 Jun 13, 2026 Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema Jun 13, 2026 Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules Jun 12, 2026 Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1 Jun 12, 2026